Inflammation in Parkinson's disease: An update

Current Opinion in Investigational Drugs

Volumn 9, Issue 5, 2008, Pages 478-484

  Smith, P F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Anti inflammatory; Inflammation; NSAID; Parkinson's disease

Indexed keywords

ACETYLSALICYLIC ACID; APIGENIN; BIOCHANIN A; IBUPROFEN; INTERLEUKIN 1BETA; MINOCYCLINE; NALOXONE; VALPROIC ACID;

ARTHRALGIA; CLINICAL STUDY; CLINICAL TRIAL; EVALUATION; HUMAN; INFLAMMATION; MEDICAL RESEARCH; NAUSEA; NONHUMAN; PARKINSON DISEASE; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISCOLORATION; TOOTH DISCOLORATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZOIC ACIDS; BRIDGED COMPOUNDS; DITERPENES; DRUG EVALUATION, PRECLINICAL; GLUCOSIDES; HUMANS; INFLAMMATION; PARKINSON DISEASE; PHENANTHRENES; PURINES;

EID: 43549111605     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Teismann P, Schulz JB: Cellular pathology of Parkinson's disease: Astrocytes, microglia and inflammation. Cell Tissue Res (2004) 318(1):149-161.
2. McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 38(8):1285-1291.
3. Wilkin GP, Knott C: Glia: A curtain raiser. Adv Neurol (1999) 80:3-7.
4. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE: Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp (1999) 66:85-97.
5. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y: Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol (2003) 106(6):518-526.
6. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T: Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients. Neurosci Lett (1994) 165(1-2):208-210.
7. Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC: Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neurosci (1996) 72(2):355-363.
8. Yasuda Y, Shinagawa R, Yamada M, Mori T, Tateishi N, Fujita S: Long-lasting reactive changes observed in microglia in the striatum and substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res (2007) 1138:196-202. • An interesting study providing insight into the potential role for microglia in PD pathology. This study is important for appreciating other changes in the SN beyond the degenerating DA neurons.
9. Pattarini R, Smeyne RJ, Morgan JI: Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrimidine model of Parkinson's disease. Neurosci (2007) 145(2):645-668. • A systematic study of inflammatory mediators in the MPTP model of PD in mice. This study emphasized the importance of a series of pathological changes leading ultimately to the expression of full-blown PD.
10. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL: Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukocyte Biol (2007) 82(5):1083- 1094.
11. Liang Y, Li S, Guo Q, Zhang Y, Wen C, Zou Q, Su B: Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity. Brain Res (2007) 1178:132-140.
12. Loeffler DA, Camp DM, Conant SB: Complement activation in the Parkinson's disease substantia nigra: An immunocytochemical study. J Neuroinflammation (2006) 3:29. • An important study of complement activation in the SN in PD.
13. Kalkonde YV, Morgan WW, Sigala J, Maffi SK, Condello C, Kuziel W, Ahuja SS, Ahuja SK. Chemokines in the MPTP model of Parkinson's disease: Absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res (2007) 1128(1):1-11.
14. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S: Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA (2003) 100(9):5473-5378.
15. Feng Z, Li D, Fung PC, Pei Z, Ramsden DB, Ho SL: COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport (2003) 14(15):1927-1929.
16. Vijitruth R, Liu M, Choi D-Y, Nguyen XV, Hunter RL, Bing G: Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation (2006) 3:6. •• This is an important paper on the relationship between COX-2 and microglial activation in the MPTP model. It is particularly interesting in light of the serious adverse events associated with some COX-2 inhibitors.
17. Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF: Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci (2003) 21(3):191-198.
18. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL: Role of ICAM-1 in persisting inflammation in Parkinson's disease and MPTP monkeys. Exp Neurol (2006) 197(2):275-283.
19. Morale MC, Serra PA, L'episcopo F, Tirolo C, Caniglia S, Testa N, Gennuso F, Giaquinta G, Rocchitta G, Desole MS, Miele E et al: Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: Glia dictate resistance versus vulnerability to neurodegeneration. Neuroscience (2006) 138(3):869-878.
20. Liu H-Q, Zhang W-Y, Luo X-T, Ye Y, Zhu X-Z: Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor. Br J Pharmacol (2006) 148(3):314-325.
21. Hong Z, Wang G, Gu J, Pan J, Bai L, Zhang S, Chen SD: Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice. Eur J Neurosci (2007) 26(6):1500-1508.
22. Kreisler A, Gelé P, Wiart JF, Lhermitte M, Destée A, Bordet R: Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res (2007) 1135(1):77-84.
23. Sriram K, Miller DB, O'Callaghan JP: Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of tumor necrosis factor-α. J Neurochem (2006) 96(3):706-718. • This study provides interesting evidence of the limitations of minocycline and offers evidence for other forms of neurotoxicity mediation.
24. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G: Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem (2007) 100(5):1375-1386.
25. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong J-S, Knapp DJ, Crews FT: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia (2007) 55(5):453-462.
26. Niehaus I: Lipopolysaccharides induce inflammation-mediated neurodegeneration in the substantia nigra and cerebral cortex (A case report). In: New Trends in Alzheimer and Parkinson Related Disorders. Hanin I, Fisher A, Cacabelos R (Eds), Medimond SRl, Bologna, Italy (2004):36-39.
27. Ruano D, Revilla E, Gavilán MP, Vizuete ML, Pintado C, Vitorica J, Castaño A: Role of p38 and inducible nitric oxide synthase in the in vivo dopaminergic cells' degeneration induced by inflammatory processes after lipopolysaccharide injection. Neurosci (2006) 140(4):1157-1168.
28. Helkamaa T, Reenila I, Tuominen RK, Soinila S, Vaananen A, Tilgmann C, Rauhala P: Increased catechol-O-methyltransferase activity and protein expression in OX-42 positive cells in the substantia nigra after lipopolysaccharide microinfusion. Neurochem Int (2007) 51(6-7):412-423.
29. Abuirmeileh A, Harkavyi A, Lever R, Biggs CS, Whitton PS: Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease. J Neuroinflammation (2007) 4(1):19.
30. Park HJ, Lee PH, Ahn YW, Choi YJ, Lee G, Lee DY, Chung ES, Jin BK: Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci (2007) 26(1):79-89. •• This report provides some substance for the long-standing epidemiological evidence that smoking might be associated with a decreased risk of PD.
31. Arimoto T, Choi D-Y, Lu X, Liu M, Nguyen XV, Zheng N, Stewart CA, Kim H-C, Bing G: Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging (2007) 28(6):894-906.
32. Hunter RL, Choi D-Y, Ross SA, Bing G: Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett (2008) 432(3):198-201.
33. Bureau G, Longpré F, Martinoli MG: Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res (2008) 86(2):403-410.
34. Thomas T, Timmer M, Cesnulevicius K, Hitti E, Kotlyarov A, Gaestel M: MAPKAP kinase 2 deficiency prevents neurons from cell death by reducing neuroinflammation - relevance in a mouse model of Parkinson's disease. J Neurochem (2008): doi:10.1111/j.1471-4159.2008.05310.x.
35. Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, Pitossi FJ: Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra. Neurobiol Dis (2006) 24(1):183-193.
36. Aimi Y, McGeer PL: Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons. Parkinsonism Relat Disord (1996) 2(2):69-74.
37. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J: Aggregated α-synuclein activates microglia: A process leading to disease progression in Parkinson's disease. FASEB J (2005) 19(6):533-542.
38. Block ML, Li G, Qin L, Wu X, Pei Z, Wang T, Wilson B, Yang J, Hong JS: Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: Substance P vs. dynorphin. FASEB J (2006) 20(2):251-258.
39. Liu B, Du L, Hong J-S: Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther (2000) 293(2):607-617.
40. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, Yang S, Hong JS: Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: Role of microglia. Brain Res Mol Brain Res (2005) 134(1):162-169.
41. Elsisi NS, Darling-Reed S, Lee EY, Oriaku ET, Soliman KF: Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. Neurosci Lett (2005) 375(2):91-96.
42. Chen H-Q, Jin Z-Y, Li G-H: Biochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation. Neurosci Lett (2007) 417(2):112-117.
43. Armentero MT, Levandis G, Nappi G, Bazzini E, Blandini F: Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiol Dis (2006) 24(3):492-505.
44. Klegeris A, McGeer EG, McGeer PL: Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol (2007) 20(3):351-357. •• An excellent review of inflammation in neurodegenerative diseases and its therapeutic implications. Provides a sound basis for examining the therapeutic potential of anti-inflammatory therapy in PD treatment.
45. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A: Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol (2007) 167(1):90-95. •• One of the few studies of inflammation in PD. Data required to evaluate the potential of anti-inflammatory strategies are provided.
46. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D: Circulating interleukin-15 and RANTES chemokine in Parkinson's disease. Acta Neurol Scand (2007) 116(6):374-379.
47. Wahner AD, Bronstein JM, Bordelon YM, Ritz B: Nonsteroidal antiinflammatory drugs may protect against Parkinson disease. Neurology (2007) 69(19):1836-1842. •• An important epidemiological study of the relationship between NSAID use and the risk of PD.
48. Hernán MA, Logroscino G, García Rodríguez LA: Nonsteroidal antiinflammatory drugs and the incidence of Parkinson disease. Neurology (2006) 66(7):1097-1099. •• An important epidemiological study of the relationship between NSAID use and the risk of PD.
49. Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, Nutt JG, Griffith A, Leis B, Roberts JW, Martinez ED et al: Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord (2008) 23(1):88-95. •• An important epidemiological study of the relationship between NSAID use and the risk of PD.
50. Bornebroek M, de Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, Breteler MM: Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology (2007) 28(4):193-196. •• An important epidemiological study of the relationship between NSAID use and the risk of PD.
51. Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK: Smoking, caffeine, and nonsteroidal antiinflammatory drugs in families with Parkinson disease. Arch Neurol (2007) 64(4):576-580. •• An important epidemiological study of the relationship between NSAID use and the risk of PD.
52. Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA: Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study. Neurology (2006) 67(3):494-496. •• An important epidemiological study of the relationship between NSAID use and the risk of PD.
53. Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H: Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord (2006) 21(7):964-969. •• An important epidemiological study of the relationship between NSAID use and the risk of PD.
54. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol (2005) 58(6):963-967. •• An important epidemiological study of the relationship between NSAID use and the risk of PD.
55. Kalda A, Yu L, Oztas E, Chen J-F: Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease. J Neurol Sci (2006) 248(1-2):9-15.
56. Svenningsson P, Le Moine C, Fisone G, Fredholm BB: Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol (1999) 59(4):355-396.
57. Ross GW, Abbott RD, Petrovitch H, White LR, Tanner CM: Relationship between caffeine intake and Parkinson's disease. J Am Med Assoc (2000) 284(11):1378-1379.
58. Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, Willett WC: Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol (2001) 50(1):56-63.
59. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE: Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology (2003) 60(5):790-795.
60. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 22(5):1763-1771.
61. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S et al: Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA (2001) 98(25):14669-14674.
62. NINDS NET-PD Investigators: A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology (2006) 66(5):664-671.
63. Parker WD Jr, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol (1989) 26(6):719-723.